Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

AVDL vs MCK vs CAH vs JAZZ vs CVS

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
AVDL
Avadel Pharmaceuticals plc

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • IE
Market Cap$2.10B
5Y Perf.+167.8%
MCK
McKesson Corporation

Medical - Distribution

HealthcareNYSE • US
Market Cap$92.15B
5Y Perf.+423.9%
CAH
Cardinal Health, Inc.

Medical - Distribution

HealthcareNYSE • US
Market Cap$43.59B
5Y Perf.+292.9%
JAZZ
Jazz Pharmaceuticals plc

Biotechnology

HealthcareNASDAQ • IE
Market Cap$14.24B
5Y Perf.+37.9%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$111.40B
5Y Perf.+13.6%

AVDL vs MCK vs CAH vs JAZZ vs CVS — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
AVDL logoAVDL
MCK logoMCK
CAH logoCAH
JAZZ logoJAZZ
CVS logoCVS
IndustryDrug Manufacturers - Specialty & GenericMedical - DistributionMedical - DistributionBiotechnologyMedical - Healthcare Plans
Market Cap$2.10B$92.15B$43.59B$14.24B$111.40B
Revenue (TTM)$249M$403.43B$250.55B$4.44B$407.90B
Net Income (TTM)$-278K$4.76B$1.56B$29M$2.93B
Gross Margin94.5%3.6%3.7%66.9%13.9%
Operating Margin1.8%1.5%0.9%13.9%1.5%
Forward P/E28.3x19.3x17.9x9.4x12.2x
Total Debt$2M$7.39B$9.35B$5.42B$93.59B
Cash & Equiv.$51M$5.69B$3.87B$1.39B$8.51B

AVDL vs MCK vs CAH vs JAZZ vs CVSLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

AVDL
MCK
CAH
JAZZ
CVS
StockMay 20Feb 26Return
Avadel Pharmaceutic… (AVDL)100267.8+167.8%
McKesson Corporation (MCK)100523.9+423.9%
Cardinal Health, In… (CAH)100392.9+292.9%
Jazz Pharmaceutical… (JAZZ)100137.9+37.9%
CVS Health Corporat… (CVS)100113.6+13.6%

Price return only. Dividends and distributions are not included.

Quick Verdict: AVDL vs MCK vs CAH vs JAZZ vs CVS

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: AVDL and MCK are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. McKesson Corporation is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. CAH, JAZZ, and CVS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
AVDL
Avadel Pharmaceuticals plc
The Defensive Pick

AVDL has the current edge in this matchup, primarily because of its strength in sleep-well-at-night.

  • Lower volatility, beta 0.23, Low D/E 2.3%, current ratio 2.75x
  • 5.0% revenue growth vs CAH's -1.9%
  • +128.5% vs MCK's +4.6%
Best for: sleep-well-at-night
MCK
McKesson Corporation
The Growth Play

MCK is the #2 pick in this set and the best alternative if growth exposure and long-term compounding is your priority.

  • Rev growth 16.2%, EPS growth 14.9%, 3Y rev CAGR 10.8%
  • 348.1% 10Y total return vs CAH's 160.8%
  • 1.2% margin vs AVDL's -0.1%
  • 5.7% ROA vs AVDL's -0.2%, ROIC 5.4% vs -76.3%
Best for: growth exposure and long-term compounding
CAH
Cardinal Health, Inc.
The Income Pick

CAH ranks third and is worth considering specifically for income & stability and defensive.

  • Dividend streak 20 yrs, beta 0.03, yield 1.1%
  • Beta 0.03, yield 1.1%, current ratio 0.94x
  • Beta 0.03 vs JAZZ's 0.65
Best for: income & stability and defensive
JAZZ
Jazz Pharmaceuticals plc
The Value Play

JAZZ is the clearest fit if your priority is value.

  • Lower P/E (9.4x vs 12.2x)
Best for: value
CVS
CVS Health Corporation
The Insurance Pick

CVS is the clearest fit if your priority is dividends.

  • 3.1% yield, vs CAH's 1.1%, (2 stocks pay no dividend)
Best for: dividends
See the full category breakdown
CategoryWinnerWhy
GrowthAVDL logoAVDL5.0% revenue growth vs CAH's -1.9%
ValueJAZZ logoJAZZLower P/E (9.4x vs 12.2x)
Quality / MarginsMCK logoMCK1.2% margin vs AVDL's -0.1%
Stability / SafetyCAH logoCAHBeta 0.03 vs JAZZ's 0.65
DividendsCVS logoCVS3.1% yield, vs CAH's 1.1%, (2 stocks pay no dividend)
Momentum (1Y)AVDL logoAVDL+128.5% vs MCK's +4.6%
Efficiency (ROA)MCK logoMCK5.7% ROA vs AVDL's -0.2%, ROIC 5.4% vs -76.3%

AVDL vs MCK vs CAH vs JAZZ vs CVS — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

AVDLAvadel Pharmaceuticals plc
FY 2024
Reportable Segment
100.0%$169M
MCKMcKesson Corporation
FY 2025
U.S. Pharmaceutical Segment
91.3%$327.7B
International Segment
4.1%$14.7B
Medical-Surgical Solutions Segment
3.2%$11.4B
Prescription Technology Solutions
1.5%$5.2B
CAHCardinal Health, Inc.
FY 2025
Pharmaceutical Member
91.9%$204.6B
GMPD
5.7%$12.6B
Other Operating Segment
2.4%$5.4B
JAZZJazz Pharmaceuticals plc
FY 2025
Xywav
39.6%$1.7B
Epidiolex/Epidyolex
25.3%$1.1B
Rylaze/Enrylaze
9.6%$403M
Zepzelca
7.3%$307M
High Sodium AG Oxybate Product Royalty Revenue
5.1%$212M
Defitelio/Defibrotide
4.8%$199M
Vyxeos
3.5%$147M
Other (4)
4.8%$201M
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B

AVDL vs MCK vs CAH vs JAZZ vs CVS — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMCKLAGGINGCVS

Income & Cash Flow (Last 12 Months)

JAZZ leads this category, winning 3 of 6 comparable metrics.

CVS is the larger business by revenue, generating $407.9B annually — 1641.4x AVDL's $249M. Profitability is closely matched — net margins range from 1.2% (MCK) to -0.1% (AVDL). On growth, AVDL holds the edge at +54.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
RevenueTrailing 12 months$249M$403.4B$250.5B$4.4B$407.9B
EBITDAEarnings before interest/tax$8M$6.8B$3.2B$994M$10.5B
Net IncomeAfter-tax profit-$278,000$4.8B$1.6B$29M$2.9B
Free Cash FlowCash after capex$35M$6.0B$4.4B$1.2B$7.4B
Gross MarginGross profit ÷ Revenue+94.5%+3.6%+3.7%+66.9%+13.9%
Operating MarginEBIT ÷ Revenue+1.8%+1.5%+0.9%+13.9%+1.5%
Net MarginNet income ÷ Revenue-0.1%+1.2%+0.6%+0.7%+0.7%
FCF MarginFCF ÷ Revenue+14.2%+1.5%+1.8%+28.1%+1.8%
Rev. Growth (YoY)Latest quarter vs prior year+54.9%+6.0%+11.0%+19.1%+6.2%
EPS Growth (YoY)Latest quarter vs prior year+100.7%+37.0%-19.5%+3.9%+63.1%
JAZZ leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

Evenly matched — JAZZ and CVS each lead in 2 of 6 comparable metrics.

At 28.7x trailing earnings, CAH trades at a 54% valuation discount to CVS's 62.8x P/E. On an enterprise value basis, CVS's 13.1x EV/EBITDA is more attractive than JAZZ's 23.8x.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
Market CapShares × price$2.1B$92.1B$43.6B$14.2B$111.4B
Enterprise ValueMkt cap + debt − cash$2.1B$93.8B$49.1B$18.3B$196.5B
Trailing P/EPrice ÷ TTM EPS-42.43x29.25x28.72x-38.86x62.81x
Forward P/EPrice ÷ next-FY EPS est.28.28x19.28x17.94x9.38x12.19x
PEG RatioP/E ÷ EPS growth rate0.75x
EV / EBITDAEnterprise value multiple18.74x16.01x23.84x13.11x
Price / SalesMarket cap ÷ Revenue12.44x0.26x0.20x3.34x0.28x
Price / BookPrice ÷ Book value/share27.88x3.21x1.47x
Price / FCFMarket cap ÷ FCF17.63x23.56x10.98x14.27x
Evenly matched — JAZZ and CVS each lead in 2 of 6 comparable metrics.

Profitability & Efficiency

MCK leads this category, winning 5 of 9 comparable metrics.

MCK delivers a 3.0% return on equity — every $100 of shareholder capital generates $3 in annual profit, vs $-0 for AVDL. AVDL carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to JAZZ's 1.26x. On the Piotroski fundamental quality scale (0–9), MCK scores 6/9 vs AVDL's 4/9, reflecting solid financial health.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
ROE (TTM)Return on equity-0.3%+3.0%+0.7%+3.9%
ROA (TTM)Return on assets-0.2%+5.7%+2.8%+0.3%+1.1%
ROICReturn on invested capital-76.3%+5.4%+33.8%+2.1%+5.0%
ROCEReturn on capital employed-34.9%+30.5%+19.2%+2.2%+6.1%
Piotroski ScoreFundamental quality 0–946655
Debt / EquityFinancial leverage0.02x1.26x1.24x
Net DebtTotal debt minus cash-$50M$1.7B$5.5B$4.0B$85.1B
Cash & Equiv.Liquid assets$51M$5.7B$3.9B$1.4B$8.5B
Total DebtShort + long-term debt$2M$7.4B$9.3B$5.4B$93.6B
Interest CoverageEBIT ÷ Interest expense0.66x33.79x6.38x-3.72x2.11x
MCK leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

Evenly matched — MCK and CAH each lead in 2 of 6 comparable metrics.

A $10,000 investment in MCK five years ago would be worth $38,689 today (with dividends reinvested), compared to $11,700 for CVS. Over the past 12 months, AVDL leads with a +128.5% total return vs MCK's +4.6%. The 3-year compound annual growth rate (CAGR) favors CAH at 31.5% vs CVS's 11.0% — a key indicator of consistent wealth creation.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
YTD ReturnYear-to-date+0.6%-8.5%-9.5%+31.1%+10.6%
1-Year ReturnPast 12 months+128.5%+4.6%+22.0%+123.7%+34.7%
3-Year ReturnCumulative with dividends+45.8%+106.4%+127.3%+63.7%+36.6%
5-Year ReturnCumulative with dividends+164.9%+286.9%+235.7%+30.0%+17.0%
10-Year ReturnCumulative with dividends+113.0%+348.1%+160.8%+53.7%+3.5%
CAGR (3Y)Annualised 3-year return+13.4%+27.3%+31.5%+17.8%+11.0%
Evenly matched — MCK and CAH each lead in 2 of 6 comparable metrics.

Risk & Volatility

Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

CAH is the less volatile stock with a 0.03 beta — it tends to amplify market swings less than JAZZ's 0.65 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 98.5% from its 52-week high vs MCK's 75.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
Beta (5Y)Sensitivity to S&P 5000.23x0.04x0.03x0.65x0.05x
52-Week HighHighest price in past year$23.57$999.00$233.60$230.40$88.63
52-Week LowLowest price in past year$8.44$637.00$137.75$97.50$58.35
% of 52W HighCurrent price vs 52-week peak+91.8%+75.3%+79.3%+98.5%+98.5%
RSI (14)Momentum oscillator 0–10061.816.233.277.069.3
Avg Volume (50D)Average daily shares traded0757K1.7M866K7.4M
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

Analyst Outlook

Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: AVDL as "Buy", MCK as "Buy", CAH as "Buy", JAZZ as "Buy", CVS as "Buy". Consensus price targets imply 34.8% upside for CAH (target: $250) vs -4.8% for JAZZ (target: $216). For income investors, CVS offers the higher dividend yield at 3.06% vs MCK's 0.36%.

MetricAVDL logoAVDLAvadel Pharmaceut…MCK logoMCKMcKesson Corporat…CAH logoCAHCardinal Health, …JAZZ logoJAZZJazz Pharmaceutic…CVS logoCVSCVS Health Corpor…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$22.50$1006.50$249.67$216.14$95.20
# AnalystsCovering analysts1431334841
Dividend YieldAnnual dividend ÷ price+0.4%+1.1%+3.1%
Dividend StreakConsecutive years of raises17200
Dividend / ShareAnnual DPS$2.69$2.04$2.67
Buyback YieldShare repurchases ÷ mkt cap0.0%+3.4%+1.8%+0.9%0.0%
Evenly matched — CAH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

JAZZ leads in 1 of 6 categories (Income & Cash Flow). MCK leads in 1 (Profitability & Efficiency). 4 tied.

Best OverallMcKesson Corporation (MCK)Leads 1 of 6 categories
Loading custom metrics...

AVDL vs MCK vs CAH vs JAZZ vs CVS: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is AVDL or MCK or CAH or JAZZ or CVS a better buy right now?

For growth investors, Avadel Pharmaceuticals plc (AVDL) is the stronger pick with 504.

8% revenue growth year-over-year, versus -1. 9% for Cardinal Health, Inc. (CAH). Cardinal Health, Inc. (CAH) offers the better valuation at 28. 7x trailing P/E (17. 9x forward), making it the more compelling value choice. Analysts rate Avadel Pharmaceuticals plc (AVDL) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — AVDL or MCK or CAH or JAZZ or CVS?

On trailing P/E, Cardinal Health, Inc.

(CAH) is the cheapest at 28. 7x versus CVS Health Corporation at 62. 8x. On forward P/E, Jazz Pharmaceuticals plc is actually cheaper at 9. 4x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — AVDL or MCK or CAH or JAZZ or CVS?

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to +17. 0% for CVS Health Corporation (CVS). Over 10 years, the gap is even starker: MCK returned +348. 1% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — AVDL or MCK or CAH or JAZZ or CVS?

By beta (market sensitivity over 5 years), Cardinal Health, Inc.

(CAH) is the lower-risk stock at 0. 03β versus Jazz Pharmaceuticals plc's 0. 65β — meaning JAZZ is approximately 1812% more volatile than CAH relative to the S&P 500. On balance sheet safety, Avadel Pharmaceuticals plc (AVDL) carries a lower debt/equity ratio of 2% versus 126% for Jazz Pharmaceuticals plc — giving it more financial flexibility in a downturn.

05

Which is growing faster — AVDL or MCK or CAH or JAZZ or CVS?

By revenue growth (latest reported year), Avadel Pharmaceuticals plc (AVDL) is pulling ahead at 504.

8% versus -1. 9% for Cardinal Health, Inc. (CAH). On earnings-per-share growth, the picture is similar: Cardinal Health, Inc. grew EPS 87. 0% year-over-year, compared to -167. 5% for Jazz Pharmaceuticals plc. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — AVDL or MCK or CAH or JAZZ or CVS?

McKesson Corporation (MCK) is the more profitable company, earning 0.

9% net margin versus -28. 9% for Avadel Pharmaceuticals plc — meaning it keeps 0. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JAZZ leads at 5. 3% versus -25. 1% for AVDL. At the gross margin level — before operating expenses — AVDL leads at 91. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is AVDL or MCK or CAH or JAZZ or CVS more undervalued right now?

On forward earnings alone, Jazz Pharmaceuticals plc (JAZZ) trades at 9.

4x forward P/E versus 28. 3x for Avadel Pharmaceuticals plc — 18. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CAH: 34. 8% to $249. 67.

08

Which pays a better dividend — AVDL or MCK or CAH or JAZZ or CVS?

In this comparison, CVS (3.

1% yield), CAH (1. 1% yield), MCK (0. 4% yield) pay a dividend. AVDL, JAZZ do not pay a meaningful dividend and should not be held primarily for income.

09

Is AVDL or MCK or CAH or JAZZ or CVS better for a retirement portfolio?

For long-horizon retirement investors, Cardinal Health, Inc.

(CAH) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 03), 1. 1% yield, +160. 8% 10Y return). Both have compounded well over 10 years (CAH: +160. 8%, JAZZ: +53. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between AVDL and MCK and CAH and JAZZ and CVS?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: AVDL is a small-cap high-growth stock; MCK is a mid-cap high-growth stock; CAH is a mid-cap quality compounder stock; JAZZ is a mid-cap quality compounder stock; CVS is a mid-cap income-oriented stock. CAH, CVS pay a dividend while AVDL, MCK, JAZZ do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

AVDL

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 27%
  • Gross Margin > 56%
Run This Screen
Stocks Like

MCK

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

CAH

Stable Dividend Mega-Cap

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 0.5%
Run This Screen
Stocks Like

JAZZ

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 9%
  • Gross Margin > 40%
Run This Screen
Stocks Like

CVS

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Dividend Yield > 1.2%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform AVDL and MCK and CAH and JAZZ and CVS on the metrics below

Revenue Growth>
%
(AVDL: 54.9% · MCK: 6.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.